1. Home
  2. TREO vs RNTX Comparison

TREO vs RNTX Comparison

Compare TREO & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tactical Resources Corp. Common Shares

TREO

Tactical Resources Corp. Common Shares

N/A

Current Price

$4.04

Market Cap

54.6M

ML Signal

N/A

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$0.77

Market Cap

65.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TREO
RNTX
Founded
N/A
2001
Country
Canada
United States
Employees
N/A
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
54.6M
65.3M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
TREO
RNTX
Price
$4.04
$0.77
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
83.7K
348.6K
Earning Date
N/A
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
44.16
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.58
$0.69
52 Week High
$5.90
$2.18

Technical Indicators

Market Signals
Indicator
TREO
RNTX
Relative Strength Index (RSI) N/A 50.10
Support Level N/A $0.71
Resistance Level N/A $0.88
Average True Range (ATR) 0.00 0.06
MACD 0.00 0.00
Stochastic Oscillator 0.00 36.77

Price Performance

Historical Comparison
TREO
RNTX

About TREO Tactical Resources Corp. Common Shares

Tactical Resources Corp is an exploration & development company focused on the rare earth elements (REE) that drive the green technologies of the future. Its projects include Lac Ducharme Project, Sierra Blanca Quarry Project, and Peak Project.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: